Intellia's Angioedema Drug: Enrollment Complete, Shares Soar

Intellia completed enrollment for lonvo-z, a gene-editing drug for severe swelling (HAE). It aims to be the first one-time treatment for HAE, a rare genetic disease. Top study data is expected in early 2026, with a potential U.S. launch in early 2027. Intellia's shares surged on the news.